NEW YORK, Sept. 13, 2017 -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Depomed, Inc. (NASDAQ:DEPO) from February 26, 2015 through August 7, 2017, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Depomed investors under the federal securities laws.
To join the Depomed class action, go to http://rosenlegal.com/cases-1185.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Depomed engaged in questionable practices in connection with the sales and marketing of the Company’s opioid products; (2) the foregoing conduct, when it became known, would likely subject the Company to heightened legal and regulatory scrutiny; and (3) as a result, Depomed’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 17, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://rosenlegal.com/cases-1185.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Since 2014, Rosen Law Firm has been ranked #2 in the nation by Institutional Shareholder Services for the number of securities class action settlements annually obtained for investors.
-------------------------------
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
Kevin Chan, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 34th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
[email protected]
[email protected]
www.rosenlegal.com


Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
UPS and Teamsters Reach Agreement to Limit Driver Severance Program
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions
Luxury Car Sales in the Middle East Take a Hit Amid Iran War
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding?
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 



